One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi

Cecilia Kanyama,Sile F. Molloy,Adrienne K. Chan,Duncan Lupiya,Chimwemwe Chawinga,Jack Adams,Philip Bright,David G. Lalloo,Robert S. Heyderman,Olivier Lortholary,Shabbar Jaffar,Angela Loyse,Joep J. van Oosterhout,Mina C. Hosseinipour,Thomas S. Harrison

CLINICAL INFECTIOUS DISEASES（2020）

Cited 14|Views28

No score

Abstract

In Malawi, 236 participants from the Advancing Cryptococcal Meningitis Treatment for Africa trial were followed for 12 months. The trial outcomes reported at 10 weeks were sustained to 1 year. One-week amphotericin B plus flucytosine was associated with the lowest 1 year mortality (27.5% [95% confidence interval, 16.3 to 44.1]).

Translated text

Key words

cryptococcal meningitis,treatment,long-term follow-up,Malawi,HIV

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined